Drug Profile

Autologous muscle precursor cell therapy - MUVON Therapeutics

Latest Information Update: 09 Dec 2025

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator University of Zurich
Developer MUVON Therapeutics
Class Cell therapies
Mechanism of Action Cell replacements

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity No

Highest Development Phases

Phase II Urinary incontinence
Preclinical Faecal incontinence; Unspecified

Most Recent Events

03 Dec 2025 Efficacy and adverse events data from the phase II SUISSE-MPC2 trial in Urinary incontinencereleased by MUVON Therapeutics
05 Aug 2025 Preclinical trials in Faecal Incontinence in Switzerland (Transurethral) (Muvon Therpaeutic pipeline, August 2025)
05 Aug 2025 Preclinical trials in Unspecified in Switzerland (Transurethral) (Muvon Therpaeutic pipeline, August 2025)

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com